IE
RARE icon

Israel Englander’s Ultragenyx Pharmaceutical RARE Stock Holding History

Israel Englander’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,500
Closed -$564K – 6390
2025
Q2 		$564K Buy
+15,500
New +$559K ﹤0.01% 4824

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Israel Englander's RARE Position: Q2 2026 in Review

Israel Englander reduced its Ultragenyx Pharmaceutical (RARE) stake by 57% in Q2 2026, selling an estimated $25.1M and leaving 760,825 shares worth $25.4M. The position accounts for 0.01% of the portfolio, ranked #1409.

Israel Englander first reported a position in RARE in Q1 2014 and has held it in 42 quarters since. The position peaked at $76.1M in Q2 2024. 308 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Israel Englander held 760,825 shares of Ultragenyx Pharmaceutical worth $25.4M as of Q2 2026.
  • Israel Englander sold 1,011,359 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $25.1M.
  • Ultragenyx Pharmaceutical made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1409 holding.
  • Israel Englander first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 42 quarters since.
  • Israel Englander's Ultragenyx Pharmaceutical position peaked at $76.1M in Q2 2024.
  • 308 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.